Poly-ε-caprolactone (PCL) nanoparticles in breast cancer therapy: bridging bench research and clinical potential

Key Points

• PCL nanoparticles demonstrate enhanced drug delivery efficacy in breast cancer therapy, with improved outcomes.
• Key evidence indicates that treatment using PCL nanoparticles resulted in a notable increase in therapeutic effectiveness.
• Analysis of bench and clinical data shows how PCL nanoparticles can bridge research into practical applications in breast cancer treatment.
• Highlighting a promising avenue for improving breast cancer therapy, with a focus on enhancing biocompatibility and delivery mechanisms.